Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
Acelity falls to 3M, but the conglomerate has taken on a great deal of debt and could see its credit rating fall.
A flop in a small depression trial hits Vistagen Therapeutics, but the group insists that all is well ahead of its main event.
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.